Researchers tested VER-01, a cannabis-based extract, on adults with persistent lower back pain. Patients reported meaningful pain relief over several months. Unlike smoking cannabis, VER-01 provides controlled doses without psychoactive highs. Chronic lower back pain affects over 619 million people worldwide, making it the leading cause of disability. Conventional treatments include opioids, which carry high addiction risks, and NSAIDs like ibuprofen, which may cause long-term heart or gastrointestinal problems. Patients often struggle to find effective options, highlighting the urgent need for safer therapies.
Clinical Trial Shows Promising Results
The trial enrolled 820 adults who did not find relief from standard non-opioid medications. Researchers divided participants into two groups: one received VER-01, and the other received a placebo. Patients recorded pain levels on a 0–10 scale, with 10 as the worst. After three months, VER-01 users reported a 1.9-point pain reduction, while the placebo group improved by only 0.6 points. Over six months, VER-01 patients gained an additional 1.1-point improvement and experienced better sleep and mobility. Researchers published the results in Nature Medicine, emphasizing the clinical significance of the findings. Neuroscientist Jan Vollert called the results encouraging but stressed the need for further studies.
Safety Profile and Future Directions
VER-01 contains 2.5 milligrams of THC per dose and other cannabis-derived compounds. Patients experienced minor side effects, including dizziness, nausea, and drowsiness, but researchers observed no dependence or abuse. Experts caution that VER-01 differs significantly from smoking cannabis. Vollert compared them to eating hazelnuts versus Nutella: similar origins but entirely different effects. Researchers plan to test VER-01 against opioids in future trials to assess efficacy and safety. If confirmed, the extract could offer a safer alternative for millions living with chronic lower back pain, reducing reliance on addictive or high-risk medications.
